Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Nivolumab Triplet Elicits Clinically Meaningful Responses in Advanced HCC

January 25th 2020

The triplet regimen of nivolumab (Opdivo), ipilimumab (Yervoy), and cabozantinib (Cabometyx) achieved clinically meaningful responses in patients with advanced hepatocellular carcinoma who were either sorafenib (Nexavar)-naïve, or resistant to or intolerant of sorafenib.

Chemo With or Without Veliparib Active in BRCA/PALB2+ Pancreatic Cancer

January 25th 2020

The combination of gemcitabine plus cisplatin with or without veliparib is highly active in patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation.

Frontline Lenvatinib with Subsequent Therapy Improves Survival in Unresectable HCC

January 25th 2020

Patients with unresectable hepatocellular carcinoma who were randomized to first-line lenvatinib (Lenvima), compared with sorafenib (Nexavar), and received subsequent anticancer procedures experienced prolonged overall survival.

Dr. Morris on Optimizing CRC Treatment Based on Oligometastatic Status

January 25th 2020

Van Morris, MD, discusses research around treatment for patients with unresectable colorectal cancer.

Addition of Cabozantinib to Ipi/Nivo Shows Promising Antitumor Activity in Advanced HCC

January 25th 2020

The triplet combination of cabozantinib, nivolumab, and ipilimumab induced higher response rates, progression-free survival, and overall survival compared with nivolumab plus cabozantinib in patients with advanced hepatocellular carcinoma.

Nivolumab/Ramucirumab Plus Chemo Highly Active in Second-Line Gastric Cancer

January 25th 2020

The triplet of nivolumab, ramucirumab and paclitaxel showed promising antitumor activity with durable responses in a phase II study of patients with advanced gastric cancer.

Dr. Macarulla Discusses Rapid Progressors in the POLO Trial

January 24th 2020

Teresa Macarulla, MD, discusses a new finding from the phase III POLO trial regarding patients who rapidly progressed on treatment.

Larotrectinib Efficacy Confirmed in TRK+ GI Cancer

January 24th 2020

The efficacy of larotrectinib has been confirmed in patients with heavily pretreated TRK fusion–positive gastrointestinal cancers.

Pembrolizumab Shows Enhanced Efficacy in High PD-L1 Gastric Cancer

January 24th 2020

Pembrolizumab monotherapy in the first and later lines of therapy leads to more durable responses and meaningfully improves overall survival compared with chemotherapy in patients with advanced gastric/gastroesophageal junction cancer with a high number of PD-L1–expressing cells in the tumor, lymphocytes, and macrophages.

Dr. Cline on Data With PARP Inhibitors in Pancreatic Cancer

January 23rd 2020

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.

Dr. Abou-Alfa on Ramucirumab as Second-Line Therapy for Hepatocellular Carcinoma

January 23rd 2020

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Blood-Based Assay Identifies Hard-to-Detect Gastrointestinal Cancers

January 22nd 2020

A DNA methylation-based cell-free DNA assay demonstrated high specificity and accurate localization of cancers to specific regions of the gastrointestinal tract.

Surufatinib Improves PFS in Advanced Pancreatic Neuroendocrine Tumors

January 22nd 2020

Surufatinib improved progression-free survival compared with placebo in patients with low- or intermediate-grade advanced pancreatic neuroendocrine tumors for whom there is no effective therapy.

Dr. Ribeiro on the Role of Surgery in Pancreatic Cancer

January 22nd 2020

Afonso Ribeiro, MD, discusses the role of surgery in treating patients with pancreatic cancer.

FDA Grants Durvalumab Plus Tremelimumab Orphan Drug Status in HCC

January 22nd 2020

The FDA has granted an orphan drug designation to durvalumab and tremelimumab for the treatment of patients with hepatocellular carcinoma.

Dr. Choti on Future Treatment of Patients With Stage IV Pancreatic Cancer

January 21st 2020

Michael A. Choti, MD, discusses the future of treatment for patients with stage IV pancreatic cancer.

Tabernero Finds New Paths in Gastrointestinal Treatment Landscape

January 19th 2020

Josep Tabernero, MD, PHD, MSc, is best known for applying translational research against gastrointestinal tumors, with particular focus on colorectal cancer.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Ribeiro on Criteria for Determining Borderline Resectability in Pancreatic Cancer

January 18th 2020

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Investigators Test Breakthrough-Designated Triplet in First-Line CRC

January 17th 2020

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?